Life Science Investing Gilead's Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial
Life Science Investing Gilead's Livdelzi® Demonstrates Sustained Efficacy in Primary Biliary Cholangitis , Offering Alkaline Phosphatase Reduction, Itch Relief and Potential to Slow Disease Progression
Life Science Investing Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025
Life Science Investing Gilead Sciences Wins Prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product With Yeztugo®
Life Science Investing LYVDELZI® RECEIVES HEALTH CANADA APPROVAL FOR THE TREATMENT OF PRIMARY BILIARY CHOLANGITIS
Life Science Investing Gilead to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025
Life Science Investing Trodelvy® Reduces Risk of Disease Progression or Death by 38% Versus Chemotherapy as First-Line Therapy in Patients With Metastatic Triple-Negative Breast Cancer in ASCENT-03 Study
Life Science Investing Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care With New Data at ESMO 2025
Life Science Investing Gilead Sciences to Release Third Quarter 2025 Financial Results on Thursday, October 30, 2025
Life Science Investing Gilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries
life science investing Gilead Sciences and Arcus Biosciences Expand Partnership to Include Research Programs in Inflammation
